Christoper Mutz

Christopher Mutz currently serves as the Head of Rare Disease, bringing a wealth of experience from his previous roles in the pharmaceutical sector. He spent over eight years at Alexion Pharmaceuticals, where he most recently held the position of Vice President of the U.S. Neurology Business Unit. In this role, he was instrumental in the successful U.S. launch of Soliris for gMG and NMOSD. Prior to this, Mutz served as Vice President and National Sales Director of the U.S. Metabolic Business Unit at Alexion. His career also includes over 11 years in various commercial roles at Merck and Co., showcasing a trajectory of increasing responsibility. Mutz’s academic background includes a BA in Biology from the University of Virginia and an MBA from the Johnson Graduate School of Management at Cornell University.